Target

BRD4

Bromodomain-containing protein 4

0open trials
2trials in total
76publications
0researchers

Diseases

Childhood cancers1 trial
Melanoma1 trial
Neuroblastoma1 trial
Sarcoma1 trial

The last 24 months

New trials, publications, preprints and grants on this target, month by month.

TrialsPublicationsPreprintsGrants

Publication
Development of Trivalent BRD4 PROTACs: Advancing Targeted Protein Degradation Strategies.
12 Nov 2026· ChemMedChem· PUBMED
Publication
JQ1 targeting BRD4 enhances cisplatin-induced pyroptosis via LDHA-mediated ROS release to potentially overcome chemoresistance in bladder cancer.
5 Nov 2026· Biochimica et biophysica acta. Molecular basis of disease· PUBMED
Publication
Identification of BRD4 as a Shared Diagnostic Biomarker Between Bipolar Disorder and Multiple Sclerosis Using Machine Learning.
19 Oct 2026· Current issues in molecular biology· PUBMED
Publication
The ENL-USP7 complex regulates HIV latency through BRD4 protein stabilization.
10 Oct 2026· Cell reports· PUBMED
Publication
Disrupting BRD4-BD1-p62 engagement restores protective autophagy.
8 Oct 2026· Cell chemical biology· PUBMED
Publication
Galectin-3 accelerates the progression of cerebral infarction by regulating the ERK/ROS/BRD4-mediated P2X7R/MerTK balance in microglia.
8 Oct 2026· Biochemical and biophysical research communications· PUBMED
Publication
Discovery of a novel BRD4 inhibitor for the treatment of acute myeloid leukemia.
8 Oct 2026· Bioorganic chemistry· PUBMED
Publication
Iterative Optimization of Photoactivatable BRD4 Degraders for Aging-Amplified Immunotherapy in Patient-Derived Lung Cancer Organoids.
4 Oct 2026· Angewandte Chemie (International ed. in English)· PUBMED
Publication
Renal Tubular Epithelial Cells Senescence Induced by 1-Aminopyrene Activates Fibroblast via BRD4 Driven Senescence-Associated Secretory Phenotype Signaling.
1 Oct 2026· Journal of biochemical and molecular toxicology· PUBMED
Publication
Corrigendum to "PCIF1-mediated m6Am modification activates USP5/BRD4 Axis to promote glycolysis-driven immunosuppression in multiple myeloma" [Int. Immunopharmacol. 186 (2026), 117062].
26 Sept 2026· International immunopharmacology· PUBMED
Publication
Cell Type-Specific Roles for BRD4 in Heart Failure.
26 Sept 2026· Current cardiology reports· PUBMED
Publication
Erratum: CYP19A1 is downregulated by BRD4 and suppresses castration-resistant prostate cancer cell invasion and proliferation by decreasing AR expression.
25 Sept 2026· American journal of cancer research· PUBMED
Publication
Mutant ASXL1 Cooperates with MECOM and BRD4 to Drive Transcriptional Dysregulation in Human Hematopoiesis.
22 Sept 2026· Blood· PUBMED
Publication
Erratum for the Research Article, "Coinhibition of topoisomerase 1 and BRD4-mediated pause release selectively kills pancreatic cancer via readthrough transcription" by D. Cameron et al.
18 Sept 2026· Science advances· PUBMED
Publication
Targeted BRD4 degradation by multivalent dendrimer-based PROTAC and its combined effects with chemotherapy on colon cancer.
17 Sept 2026· Biomaterials· PUBMED
Publication
Inhibition of Endothelial BRD4 Alleviates Lupus Nephritis Partly Through Interacting With FLI-1.
7 Sept 2026· Arthritis & rheumatology (Hoboken, N.J.)· PUBMED
Publication
Laryngeal NUT Carcinoma With BRD4::NUTM1 Fusion: A 4-Year Clinical Course Highlighting the Limitations of Current Multimodal Therapy.
1 Sept 2026· Cancer reports (Hoboken, N.J.)· PUBMED
Publication
[Overexpression of JMJD6 Drives Immune Evasion via the BRD4-IRF1-PD-L1 Axis and Promotes Malignancy in Gastric Cancer].
1 Sept 2026· Gan to kagaku ryoho. Cancer & chemotherapy· PUBMED
Publication
In vivo validation of intramolecular bivalent glues targeting PSMA reveals potent and tissue-selective BRD4 degradation in prostate cancer.
11 Aug 2026· Acta pharmaceutica Sinica. B· PUBMED
Publication
BRD4 contributes to the cytokine-induced acquisition of an IL-13RA2-positive inflammatory fibroblast phenotype.
5 Aug 2026· Journal of Crohn's & colitis· PUBMED
Publication
BRD4 recruitment into HP1 condensates desilences transcription without erasure of repressive chromatin.
5 Aug 2026· Nature cell biology· PUBMED
Publication
An antibody-PROTAC conjugate targets BRD4/c-Myc/PD-L1 to enhance immunotherapy efficacy in triple-negative breast cancer.
29 Jul 2026· Cell reports. Medicine· PUBMED
Publication
Huangqi-Danshen Decoction Alleviates Cardiac Fibrosis Following Myocardial Infarction by Inhibiting USP22 to Enhance the Ubiquitination of BRD4.
21 Jul 2026· Phytomedicine : international journal of phytotherapy and phytopharmacology· PUBMED
Publication
HBO1 suppresses anti-tumor immunity of CD8⁺ T Cells in thyroid cancer by recruiting BRD4 to regulate VTCN1 expression.
17 Jul 2026· Cancer immunology, immunotherapy : CII· PUBMED
Publication
Corrigendum to "BRD4 inhibitor suppresses melanoma metastasis via the SPINK6 EGFR-EphA2 pathway" [Pharmacol. Res. 187 (2023) 106609].
14 Jul 2026· Pharmacological research· PUBMED
Publication
GID4-Recruiting PROTACs for BRD4 Degradation Overcome Resistance Driven by CRBN and VHL Deficiency.
5 Jul 2026· Journal of medicinal chemistry· PUBMED
Publication
PCIF1-mediated m6Am modification activates USP5/BRD4 axis to promote glycolysis-driven immunosuppression in multiple myeloma.
1 Jul 2026· International immunopharmacology· PUBMED
Publication
BRD4-mediated histone H4K12 lactylation drives ovarian cancer progression by activating the Ube2v1-DDX3X ubiquitination axis.
29 Jun 2026· Journal of translational medicine· PUBMED
Publication
Hesperidin suppressed high-fat diet induced obesity via modulating ROS/JNK/BRD4/SHP2 signaling induced lipogenesis.
25 Jun 2026· Scientific reports· PUBMED
Publication
Targeting BRD4 in gastric cancer: promoting apoptosis and suppressing tumor progression.
24 Jun 2026· Frontiers in pharmacology· PUBMED

Who works on it

Researchers who published on this target. Leave out your own co-author circle to find people you do not know yet.

No published researcher profile on this target yet.

We look for a fixed list of target names in titles, keywords, intervention names and MeSH terms. A mention does not prove that the work is aimed at that target.

Report an error